Roles and Molecular Mechanisms of Biomarkers in Hepatocellular Carcinoma with Microvascular Invasion : A Review
© 2023 Authors..
Hepatocellular carcinoma (HCC) being a leading cause of cancer-related death, has high associated mortality and recurrence rates. It has been of great necessity and urgency to find effective HCC diagnosis and treatment measures. Studies have shown that microvascular invasion (MVI) is an independent risk factor for poor prognosis after hepatectomy. The abnormal expression of biomacromolecules such as circ-RNAs, lncRNAs, STIP1, and PD-L1 in HCC patients is strongly correlated with MVI. Deregulation of several markers mentioned in this review affects the proliferation, invasion, metastasis, EMT, and anti-apoptotic processes of HCC cells through multiple complex mechanisms. Therefore, these biomarkers may have an important clinical role and serve as promising interventional targets for HCC. In this review, we provide a comprehensive overview on the functions and regulatory mechanisms of MVI-related biomarkers in HCC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal of clinical and translational hepatology - 11(2023), 5 vom: 28. Okt., Seite 1170-1183 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhao, Xudong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Revised 15.08.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.14218/JCTH.2022.00013S |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360766293 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360766293 | ||
| 003 | DE-627 | ||
| 005 | 20231226083719.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.14218/JCTH.2022.00013S |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1202.xml |
| 035 | |a (DE-627)NLM360766293 | ||
| 035 | |a (NLM)37577231 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhao, Xudong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Roles and Molecular Mechanisms of Biomarkers in Hepatocellular Carcinoma with Microvascular Invasion |b A Review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 Authors. | ||
| 520 | |a Hepatocellular carcinoma (HCC) being a leading cause of cancer-related death, has high associated mortality and recurrence rates. It has been of great necessity and urgency to find effective HCC diagnosis and treatment measures. Studies have shown that microvascular invasion (MVI) is an independent risk factor for poor prognosis after hepatectomy. The abnormal expression of biomacromolecules such as circ-RNAs, lncRNAs, STIP1, and PD-L1 in HCC patients is strongly correlated with MVI. Deregulation of several markers mentioned in this review affects the proliferation, invasion, metastasis, EMT, and anti-apoptotic processes of HCC cells through multiple complex mechanisms. Therefore, these biomarkers may have an important clinical role and serve as promising interventional targets for HCC. In this review, we provide a comprehensive overview on the functions and regulatory mechanisms of MVI-related biomarkers in HCC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a Hepatocellular carcinoma | |
| 650 | 4 | |a Microvascular invasion | |
| 650 | 4 | |a Molecular mechanism | |
| 650 | 4 | |a Progress | |
| 700 | 1 | |a Wang, Yudan |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Haoming |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Shuqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Ziyue |e verfasserin |4 aut | |
| 700 | 1 | |a He, Risheng |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Nanfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hang |e verfasserin |4 aut | |
| 700 | 1 | |a You, Junqi |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jinglin |e verfasserin |4 aut | |
| 700 | 1 | |a Yam, Judy Wai Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Cui, Yunfu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical and translational hepatology |d 2013 |g 11(2023), 5 vom: 28. Okt., Seite 1170-1183 |w (DE-627)NLM252610520 |x 2310-8819 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:5 |g day:28 |g month:10 |g pages:1170-1183 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.14218/JCTH.2022.00013S |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 5 |b 28 |c 10 |h 1170-1183 | ||